With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

The PBM plans to stop requiring coverage reauthorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...

The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat ...

Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Healthcare companies rose as traders sought out sectors that are less vulnerable to swings in economic growth and inflation prospects.

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company ...

Pfizer proudly flaunts its “World’s Most Ethical Companies” award, but this honor is a pay-to-play scheme, not a genuine ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $15,001 and ...